Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
In Vitro Enzymatic Inhibitory Activity Assay from US Patent US20240132489: "AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF"
Assay data:55 Active, 55 Activity ≤ 1 µM, 55 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
KRAS G12C-GDP Exchange Assay from US Patent US20240109893: "PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR"
Assay data:22 Active, 8 Activity ≤ 1 nM, 22 Activity ≤ 1 µM, 22 Tested
ADP-Glo Kinase Assay from US Patent US20240101538: "PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER"
Assay data:3 Active, 3 Activity ≤ 1 µM, 10 Tested
SOS1 GDP TR-FRET Assay from US Patent US20240092803: "BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF"
Assay data:14 Active, 12 Activity ≤ 1 µM, 15 Tested
CDK4/Cyclin D1 (Chelation-Enhance Fluorescence)(CHEF) Assay from US Patent US20240092761: "QUINAZOLINE COMPOUNDS AND METHODS OF USE"
Assay data:116 Active, 99 Activity ≤ 1 µM, 122 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
CDK4/Cyclin D1 Mobility Shift Assay (MSA) from US Patent US20240092761: "QUINAZOLINE COMPOUNDS AND METHODS OF USE"
Assay data:55 Active, 49 Activity ≤ 1 µM, 55 Tested
CDK2/Cyclin E1 Full Length ADP-Glo Kinase Assay from US Patent US20240092761: "QUINAZOLINE COMPOUNDS AND METHODS OF USE"
Assay data:111 Active, 104 Activity ≤ 1 µM, 122 Tested
CDK1/Cyclin B1 ADP-Glo Kinase Assay from US Patent US20240092761: "QUINAZOLINE COMPOUNDS AND METHODS OF USE"
Assay data:83 Active, 59 Activity ≤ 1 µM, 122 Tested
In Vitro Enzymatic Activity Assay from US Patent US20240083917: "Polycyclic Kinase Inhibitor"
Assay data:19 Active, 5 Activity ≤ 1 nM, 19 Activity ≤ 1 µM, 19 Tested
EGFR Kinase Assay from US Patent US20240083857: "2-Methyl-Quinazolines"
Assay data:5 Active, 2 Activity ≤ 1 µM, 301 Tested
Biochemical Assay 3 from US Patent US20240083857: "2-Methyl-Quinazolines"
Assay data:314 Active, 144 Activity ≤ 1 µM, 367 Tested
Biochemical Assay 2 from US Patent US20240083857: "2-Methyl-Quinazolines"
Assay data:367 Active, 181 Activity ≤ 1 µM, 395 Tested
Biochemical Assay 1 from US Patent US20240083857: "2-Methyl-Quinazolines"
Assay data:372 Active, 198 Activity ≤ 1 µM, 401 Tested
CDK2/Cyclin E1 HTRF Enzyme Activity Assay from US Patent US11919904: "Sulfonylamide compounds as CDK2 inhibitors"
Assay data:14 Active, 14 Activity ≤ 1 µM, 14 Tested
Coupled Nucleotide Exchange Assay from US Patent US20240059703: "HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE"
Assay data:506 Active, 473 Activity ≤ 1 µM, 513 Tested
KRAS::SOS1 AlphaScreen Binding Assay from US Patent US20240051956: "SOS1 INHIBITORS AND USES THEREOF"
Assay data:85 Active, 87 Activity ≤ 1 µM, 87 Tested
SOS-Catalyzed Nucleotide Exchange Assay from US Patent US20240043448: "Small Molecule Inhibitors of KRAS G12C Mutant"
Assay data:93 Active, 7 Activity ≤ 1 nM, 83 Activity ≤ 1 µM, 93 Tested
IC50 Assay from US Patent US11890356: "HDAC6 inhibitors and imaging agents"
Assay data:18 Active, 16 Activity ≤ 1 µM, 18 Tested
TBD from US Patent US20240034743: "TRICYCLIC COMPOUNDS AS EGFR INHIBITORS"
Assay data:135 Active, 118 Activity ≤ 1 nM, 137 Activity ≤ 1 µM, 137 Tested
Assay data:133 Active, 31 Activity ≤ 1 nM, 137 Activity ≤ 1 µM, 137 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on